| 免疫检查点抑制剂治疗少见突变非小细胞肺癌疗效的研究进展 |
| |
| 引用本文： | 李腾,李峻岭.免疫检查点抑制剂治疗少见突变非小细胞肺癌疗效的研究进展[J].中国肺癌杂志,2021(1). |
| |
| 作者姓名： | 李腾 李峻岭 |
| |
| 作者单位： | 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院 |
| |
| 摘 要： | 驱动基因的发现及针对驱动基因的靶向治疗已显著提高了肺癌患者的生存质量和时间,但目前对于BRAF、HER2、MET、RET等少见驱动基因改变肺癌患者的靶向药物的选择仍然较少。近年来免疫检查点抑制剂在肺癌治疗中取得了一定的疗效,但因为少见驱动基因突变的肺癌患者本身样本量少,开展大规模临床随机对照试验尚存在一定的困难,目前此类患者接受免疫检查点抑制剂治疗的疗效情况仍不明确。本文将对目前已掌握的免疫检查点抑制剂治疗BRAF、HER2、MET、RET等少见驱动基因改变肺癌患者的临床研究结果进行综述,以期在一定程度上为临床工作提供一些依据和参考。
|
| 关 键 词： | 肺肿瘤 少见突变 免疫检查点抑制剂 |
Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer with Rare Mutation |
| |
| Teng LI,Junling LI.Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer with Rare Mutation[J].Chinese Journal of Lung Cancer,2021(1). |
| |
| Authors: | Teng LI Junling LI |
| |
| Institution: | (National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China) |
| |
| Abstract: | Over the past several decades,advances in driven targeted therapy has revolutionized the management of oncogene-driven non-small cell lung cancer(NSCLC).However,there are only a few targeted drugs available for patients with rare mutations,such as BRAF,HER2,MET,RET,etc.In recent years,immune checkpoint inhibitors(ICIs)have demonstrated promising benefit in NSCLC.Till now,efficacy of ICIs for NSCLC with rare mutation is largely unknown.It is fairly difficult to conduct a large formal prospective controlled trials because of the rarity of these mutation.In this article,currently available real world studies based on convincing clinical evidence will be reviewed,which will ultimately facilitate our rational use of ICIs for NSCLC with rare mutation. |
| |
| Keywords: | Lung neoplasms Rare mutation Immune check point inhibitors |
| 本文献已被 维普 等数据库收录！ |
|
